Safety evaluation
hoarseness
ADVERSE EVENTS, ADVERSE REACTIONS, ADVERSE EVENT
Only 2 participants in the SGB group had transient hoarseness, a treatment-related adverse event, that did not recur during the follow-up period. No adverse events unrelated to treatment occurred. Participants in the control group did not report any adverse reactions (The incidence of adverse events in the two groups.There were no statistically significant differences in the safety evaluation between the two groups.